E 7046

Drug Profile

E 7046

Alternative Names: AN 0025; E7046

Latest Information Update: 17 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Inc
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rectal cancer; Solid tumours

Most Recent Events

  • 27 Feb 2018 Eisai terminates phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in France, USA (PO) (NCT02540291)
  • 19 Jan 2018 E 7046 licensed to Adlai Nortye worldwide, excluding Japan and part of Asia other than Mainland China
  • 08 Sep 2017 Interim adverse events, pharmacokinetics data from phase I trial in rectal cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top